8.54
0.25 (3.02%)
| Penutupan Terdahulu | 8.29 |
| Buka | 8.35 |
| Jumlah Dagangan | 592,852 |
| Purata Dagangan (3B) | 821,401 |
| Modal Pasaran | 455,830,176 |
| Harga / Jualan (P/S) | 14.74 |
| Harga / Buku (P/B) | 6.49 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2024 |
| Margin Operasi (TTM) | -739.00% |
| EPS Cair (TTM) | -2.13 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 27.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 85.89% |
| Nisbah Semasa (MRQ) | 2.88 |
| Aliran Tunai Operasi (OCF TTM) | -56.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.00 M |
| Pulangan Atas Aset (ROA TTM) | -32.81% |
| Pulangan Atas Ekuiti (ROE TTM) | -130.67% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Zevra Therapeutics, Inc. | Menurun | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.13 |
|
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 6.62% |
| % Dimiliki oleh Institusi | 54.43% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Retirement Planning Co Of New England, Inc. | 30 Sep 2024 | 499,505 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 25.00 (Maxim Group, 192.74%) | Beli |
| Median | 20.50 (140.05%) | |
| Rendah | 17.00 (JMP Securities, 99.06%) | Beli |
| Purata | 21.00 (145.90%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 8.43 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Nov 2024 | 20.00 (134.19%) | Beli | 8.97 |
| 30 Sep 2024 | 20.00 (134.19%) | Beli | 6.94 | |
| Canaccord Genuity | 14 Nov 2024 | 23.00 (169.32%) | Beli | 9.03 |
| Guggenheim | 07 Oct 2024 | 20.00 (134.19%) | Beli | 7.79 |
| JMP Securities | 24 Sep 2024 | 17.00 (99.06%) | Beli | 8.27 |
| Maxim Group | 24 Sep 2024 | 25.00 (192.74%) | Beli | 8.27 |
| Roth MKM | 24 Sep 2024 | 21.00 (145.90%) | Beli | 8.27 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |